Acadia Pharmaceuticals Shares Drop Following Disappointing Drug Trial Results
Acadia Pharmaceuticals (ACAD) experienced another significant decline in its stock price on Friday after previously reporting disappointing Phase 2 trial results for remlifanserin. The company's shares fell nearly 7%, closing at $20.68, following a drop of over $1.50. This continued the downward trend from the previous day when ACAD dropped by more than 13% after announcing that its drug failed to meet the primary endpoint in statistical significance. The RADIANT study results have raised concerns among investors about the potential for remlifanserin, which is being developed as a treatment option. The market reaction highlights investor uncertainty regarding Acadia's pipeline and future prospects following this setback.
Tickers: $ACAD